From Innovation to Inquiry — COVID-19 mRNA Vaccination and Its Global Consequences — with Special Reference to New Zealand

The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by institutional consensus, and expedited regulatory pathways. Subsequent developments revealed questions regarding safety, ethics, efficacy, and governance. This formal review, with specific reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed under Emergency Use Authorizations. A range of post-deployment signals, including immunological anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain insufficiently investigated. Regulatory responses have not met the standard of precaution typically applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date, no national authority has published comprehensive disaggregated mortality data by vaccination status.